Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Venture Capital

Pamoja Capital Leads $8.2M Series C In Drug Company

by posted 2years ago 1597 views
Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), the company announced today. Pamoja Capital, prominent pain physicians and others invested in the round. The financial support will fund a Phase 2 Proof-of-Concept study for Project AWARD (A Wound Analgesic with RapiD action).